The following table summarizes the total revenue by commercialization partner recorded in the Company’s consolidated statements of operations (in thousands):



	Year Ended December 31,
	2015		2014		2013 ⁽¹⁾
Ferring	$	2,250	$	—	$	—
Sandoz	1,736		2,514		272
Takeda Pharmaceuticals International GmbH (“Takeda”)	398		141		—
Majorelle	245		4,150		—
Recordati	194		2,454		—
Bracco SpA (“Bracco”)	16		—		669
Warner Chilcott, now a subsidiary of Allergan, Inc. ("Allergan")					646
	$	4,839	$	9,259	$	1,587

⁽¹⁾ Certain revenues related to the Company’s former subsidiaries, Scomedica SAS, NexMed Europe SAS and NexMed Pharma SAS (the “French Subsidiaries”), are not shown in the table above since they were unrelated to any of the Company’s commercialization partners.

The following table summarizes the potential future milestones the Company is eligible for by commercialization partner (in thousands) as of December 31, 2015:



Commercialization Partner	Regulatory Milestones ⁽¹⁾		Commercial Launch Milestones ⁽¹⁾		Sales Milestones ⁽¹⁾		Total
Sandoz	$	319	$	1,500	$	45,613	$	47,432
Recordati	—		1,093		37,692		38,785
Takeda	437		—		36,600		37,037
Allergan	—		25,000		—		25,000
Majorelle	2,000		—		16,934		18,934
Ferring	2,000		—		14,000		16,000
Abbott Laboratories Limited, now a subsidiary of Mylan N.V. (“Mylan”)	225		—		13,000		13,225
Bracco	—		—		4,916		4,916
Neopharm Scientific Limited (“Neopharm”)	250		—		4,000		4,250
Elis Pharmaceuticals Limited (“Elis”)	100		—		1,900		2,000
	$	5,331	$	27,593	$	174,655	$	207,579

⁽¹⁾ Certain contractual amounts have been converted to USD based on the exchange rate as of 12/31/15.